NCT07149402
Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
Not Yet Recruiting · Not specified · Assiut University · registry updated 2025-09-02
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a case-control study investigating serum IL-33 levels and their association with clinical manifestations in systemic lupus erythematosus (SLE). The study compares IL-33 levels in three groups: SLE patients with lupus nephritis, SLE patients without nephritis, and healthy controls. The goal is to clarify IL-33's role as a biomarker reflecting disease activity and organ involvement, especially renal pathology.
Inclusion
- Adults aged 18 years and older.
- Diagnosed with systemic lupus erythematosus according to the American College of Rheumatology (ACR) criteria.
- For the lupus nephritis group: confirmed diagnosis of lupus nephritis based on clinical, laboratory, and renal biopsy findings.
- For the control group: healthy individuals matched for age and sex, with no history of autoimmune or renal diseases.
Exclusion
- Patients with other autoimmune diseases. Patients with chronic infections or malignancies. Pregnant or lactating women. Patients with end-stage renal disease (ESRD) or on dialysis. Individuals who refuse to provide informed consent.